时间医学与2型糖尿病:褪黑素的新启示
综述探讨生物钟系统与糖代谢的协同关系,分析昼夜节律紊乱对代谢的影响,并梳理褪黑素信号在2型糖尿病病因中的作用及褪黑素时间药理治疗的利弊。
要点
- 昼夜节律紊乱(如轮班工作或时差)可增加心脏代谢疾病风险。
- 2型糖尿病患者夜间血清褪黑素水平低于健康个体,且睡眠障碍风险增加。
- 褪黑素水平降低及褪黑素受体突变或基因多态性与2型糖尿病风险增加相关。
核心结论
- 褪黑素作为潜在的时间治疗药物受到关注,但需权衡其时间药理治疗在疾病管理中的利弊。
研究设计与样本
- 综述,未报告检索范围。
主要发现
- 昼夜节律紊乱可干扰能量平衡与代谢稳态,增加心脏代谢疾病风险。
- 肥胖与代谢疾病可扰乱多器官系统生物钟的时序与振幅,加剧疾病进展。
- 2型糖尿病患者夜间血清褪黑素水平低于健康个体,且合并睡眠障碍风险增加。
- 褪黑素水平降低及褪黑素受体突变或基因多态性与2型糖尿病风险增加相关。
- 褪黑素影响胰岛β细胞胰岛素分泌、肝脏葡萄糖代谢及胰岛素敏感性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In mammals, the circadian timing system drives rhythms of physiology and behaviour, including the daily rhythms of feeding and activity. The timing system coordinates temporal variation in the biochemical landscape with changes in nutrient intake in order to optimise energy balance and maintain metabolic homeostasis. Circadian disruption (e.g. as a result of shift work or jet lag) can disturb this continuity and increase the risk of cardiometabolic disease. Obesity and metabolic disease can also disturb the timing and amplitude of the clock in multiple organ systems, further exacerbating disease progression. As our understanding of the synergy between the timing system and metabolism has grown, an interest has emerged in the development of novel clock-targeting pharmaceuticals or nutraceuticals for the treatment of metabolic dysfunction. Recently, the pineal hormone melatonin has received some attention as a potential chronotherapeutic drug for metabolic disease. Melatonin is well known for its sleep-promoting effects and putative activity as a chronobiotic drug, stimulating coordination of biochemical oscillations through targeting the internal timing system. Melatonin affects the insulin secretory activity of the pancreatic beta cell, hepatic glucose metabolism and insulin sensitivity. Individuals with type 2 diabetes mellitus have lower night-time serum melatonin levels and increased risk of comorbid sleep disturbances compared with healthy individuals. Further, reduced melatonin levels, and mutations and/or genetic polymorphisms of the melatonin receptors are associated with an increased risk of developing type 2 diabetes. Herein we review our understanding of molecular clock control of glucose homeostasis, detail the influence of circadian disruption on glucose metabolism in critical peripheral tissues, explore the contribution of melatonin signalling to the aetiology of type 2 diabetes, and discuss the pros and cons of melatonin chronopharmacotherapy in disease management.
引用
- Forrestel AC, Miedlich SU, Yurcheshen M, et al. Chronomedicine and type 2 diabetes: shining some light on melatonin. Diabetologia. 2016. PMID: 27981356. doi:10.1007/s00125-016-4175-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。